Evidence map›Paper›PMID 26763713›Full record

ArticleDiagnostic microbiology and infectious disease2016

Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia.

David W Kubiak, Dimitrios Farmakiotis, Viktoria Arons, Randy M Hollins, Sara E Rostas, Linda M Weiser, Lindsey R Baden, Francisco M Marty, Sophia Koo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic microbiology and infectious disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

David W KubiakDepartment of Pharmacy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Division of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. Electronic address: dwkubiak@partners.org.
Dimitrios FarmakiotisWarren Alpert Medical School of Brown University, Division of Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02115, USA.
Viktoria AronsDepartment of Pharmacy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Randy M HollinsDepartment of Pharmacy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Sara E RostasDepartment of Pharmacy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Linda M WeiserClinical Microbiology Laboratory, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Lindsey R BadenDivision of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Division of Infectious Diseases, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.
Francisco M MartyDivision of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Division of Infectious Diseases, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.
Sophia KooDivision of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Division of Infectious Diseases, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: skoo@bwh.harvard.edu.
Brigham and Women's Hospital · USHarvard University · USBrown University · US

Funding

Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold InfectionK23AI097225 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KOO, SOPHIA · 2012 to 2016
$685k
NIAID NIH HHS K23 AI097225
6 · The paper itself

Abstract

Among 302 first candidemia episodes, 210 (69.6%) were initially treated with an echinocandin or polyene (E/P) antifungal drug. In 137 (72.5%) patients with fluconazole-susceptible isolates, treatment was changed to fluconazole based on disk diffusion susceptibility testing. Clinical outcomes were not compromised in patients receiving E/P who were de-escalated to fluconazole for treatment of candidemia based on disk diffusion results.

Indexed as

Disk Diffusion Antimicrobial TestsAdolescentAdultAgedAged, 80 and overAntifungal AgentsCandidemiaCohort StudiesFemaleFluconazoleHumansMaleMiddle AgedRecurrenceRisk FactorsTreatment OutcomeAntifungal AgentsFluconazoleCandidemiaDisk diffusion susceptibility testingFluconazole

Identifiers

PMID26763713
PMCPMC4917365
OpenAlexW2230689708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.